Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate ...( BERKELEY HEIGHTS N.J. March 12 /-...),Health

BERKELEY HEIGHTS, N.J., March 12 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced financial results and progress for the quarter and year ended December 31, 2007. The Company noted significant recent milestones, including:
-- AGENDA Phase 3 trial using key biomarker initiates in melanoma

-- New oral product, G4544, completes initial Phase 1 trial; planned

505(b)(2) strategy

-- Tesetaxel, a leading oral taxane, becomes new clinical-stage product

-- Genasense(R) intermittent schedule completes Phase 1, heads to

melanoma trial

-- Decision on FDA appeal for Genasense NDA in CLL expected this quarter

"Genta now has three exceptional, high-value, clinical-stage products in our portfolio, and we achieved substantial progress on the major goals of our corporate turnaround this past year," noted Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Our most important 2007 initiative was initiation of the Phase 3 AGENDA trial, which we expect will complete accrual later this year. Positive results from AGENDA should enable submissions in 2009 for global regulatory approval. Similarly, continued aggressive development of G4544, an internally developed compound for skeletal diseases, offers us the opportunity to submit a NDA for a second product in 2009 via a streamlined 505(b)(2) regulatory strategy. Lastly, our in- licensing of worldwide rights to tesetaxel has provided us with a leading oral taxane that addresses a very large and well-characterized market. Each of these drugs offers significant partnering opportunities that will accelerate their development."

Highlights and updates of the Genta programs appear below. '/>"/>